小核酸行业系列报告（一）：小核酸成药之路——Listening to the Sound of Silence:The Road to RNA Therapeutics

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their applications from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways of Small Nucleic Acid Drug Development - ASO and siRNA represent two distinct technological pathways, with ASO focusing on RNA degradation and splicing regulation, while siRNA employs the RISC mechanism for mRNA degradation [12][26] Chemical Modifications and Stability - The report outlines four generations of chemical modifications that enhance the stability and specificity of ASO, which are crucial for their therapeutic efficacy [32][36] Delivery Breakthroughs - The report identifies the challenges of delivering small nucleic acids across cellular barriers, emphasizing the need for effective delivery systems to overcome these obstacles [40][43] Safety Optimization - Innovations in safety management, such as the development of antidotes for siRNA and toxicity control for ASO, are essential for supporting long-term use and chronic disease management [3][62] Commercialization and Boundary Expansion - The industry is moving from liver-targeted therapies to exploring delivery strategies for other tissues, with companies like Alnylam aiming for multi-organ delivery by 2030 [60][61]